Figure 4.

Transcriptomic profile of RRMM patients. (A) Principal component analysis based on genetic features: samples are represented as dots in the space identified by the 2 principal components and are color-coded based on the presence or absence of the genetic feature listed in the top label: color: present; gray, absent; empty, information not available. (B) Unsupervised clustering of the samples based on their gene expression profile. Genomic features are annotated above the horizontal white line (green, cytogenetic events; red, mutations), as is last treatment (yellow, bortezomib; light blue, lenalidomide).